147 related articles for article (PubMed ID: 36824665)
1. Extracellular Volume Fraction Calculated Using Contrast-Enhanced Computed Tomography as a Biomarker of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: A Preliminary Histopathological Analysis.
Kai K; Hamada T; Sato Y; Hiyoshi M; Imamura N; Yano K; Ikeda T; Ichihara A; Ogata S; Choijookhuu N; Hishikawa Y; Hosokawa A; Nanashima A
J Oncol; 2023; 2023():1440257. PubMed ID: 36824665
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation.
Cayet S; Pasco J; Dujardin F; Besson M; Orain I; De Muret A; Miquelestorena-Standley E; Thiery J; Genet T; Le Bayon AG
Eur J Radiol; 2017 Sep; 94():180-190. PubMed ID: 28712693
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Stevenson HL; Prats MM; Sasatomi E
BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
[TBL] [Abstract][Full Text] [Related]
4. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
5. Autotaxin is a novel surrogate marker for oxaliplatin-related sinusoidal obstruction syndrome in patients with colorectal liver metastasis.
Ishii N; Harimoto N; Seki T; Muranushi R; Hagiwara K; Tsukagoshi M; Watanabe A; Yoshida Y; Araki K; Shirabe K
Hepatol Res; 2023 Aug; 53(8):761-770. PubMed ID: 36946410
[TBL] [Abstract][Full Text] [Related]
6. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
7. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.
Hubert C; Sempoux C; Humblet Y; van den Eynde M; Zech F; Leclercq I; Gigot JF
HPB (Oxford); 2013 Nov; 15(11):858-64. PubMed ID: 23458554
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant model of oxaliplatin-induced sinusoidal obstruction syndrome.
Toda R; Seo S; Uemoto Y; Morino K; Nishino H; Nakamura N; Okuno M; Iguchi K; Sato M; Nakamura K; Taura K; Nakagawa S; Nakagawa T; Tsuruyama T; Manabe T; Kawaguchi H; Iwaisako K; Ikegawa M; Uemoto S; Hatano E
Hepatol Res; 2023 Feb; 53(2):145-159. PubMed ID: 36149410
[TBL] [Abstract][Full Text] [Related]
10. Gd-EOB-DTPA-enhanced MR findings in chemotherapy-induced sinusoidal obstruction syndrome in colorectal liver metastases.
Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
J Int Med Res; 2020 Jun; 48(6):300060520926031. PubMed ID: 32500783
[TBL] [Abstract][Full Text] [Related]
11. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
Rubbia-Brandt L; Lauwers GY; Wang H; Majno PE; Tanabe K; Zhu AX; Brezault C; Soubrane O; Abdalla EK; Vauthey JN; Mentha G; Terris B
Histopathology; 2010 Mar; 56(4):430-9. PubMed ID: 20459550
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic fibrosis by extracellular volume fraction using Contrast-enhanced computed tomography and relationship with pancreatic cancer.
Fukui H; Onishi H; Nakamoto A; Tsuboyama T; Ota T; Yano K; Enchi Y; Yamada D; Takeda Y; Kobayashi S; Fukuda Y; Eguchi H; Matsui T; Tatsumi M; Tomiyama N
Eur J Radiol; 2022 Nov; 156():110522. PubMed ID: 36113381
[TBL] [Abstract][Full Text] [Related]
13. Focal Sinusoidal Obstruction Syndrome Caused by Oxaliplatin-Induced Chemotherapy: A Case Report.
Kawai T; Yamazaki S; Iwama A; Higaki T; Sugitani M; Takayama T
Hepat Mon; 2016 Sep; 16(9):e37572. PubMed ID: 27822263
[TBL] [Abstract][Full Text] [Related]
14. Estimation of pancreatic fibrosis and prediction of postoperative pancreatic fistula using extracellular volume fraction in multiphasic contrast-enhanced CT.
Sofue K; Ueshima E; Masuda A; Shirakawa S; Zen Y; Ueno Y; Tsujita Y; Yamaguchi T; Yabe S; Tanaka T; Inomata N; Toyama H; Fukumoto T; Kodama Y; Murakami T
Eur Radiol; 2022 Mar; 32(3):1770-1780. PubMed ID: 34636963
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.
Saito R; Kawamoto Y; Nishida M; Iwai T; Kikuchi Y; Yokota I; Takagi R; Yamamura T; Ito K; Harada K; Yuki S; Komatsu Y; Sakamoto N
Int J Clin Oncol; 2022 Nov; 27(11):1780-1790. PubMed ID: 36042137
[TBL] [Abstract][Full Text] [Related]
17. Hepatic fibrosis grading with extracellular volume fraction from iodine mapping in spectral liver CT.
Yoon JH; Lee JM; Kim JH; Lee KB; Kim H; Hong SK; Yi NJ; Lee KW; Suh KS
Eur J Radiol; 2021 Apr; 137():109604. PubMed ID: 33618210
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
19. Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome.
Park S; Kim HY; Kim H; Park JH; Kim JH; Kim KH; Kim W; Choi IS; Jung YJ; Kim JS
Medicine (Baltimore); 2016 Jan; 95(2):e2454. PubMed ID: 26765438
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the extracellular volume fraction for the grading of clear cell renal cell carcinoma: first results and histopathological findings.
Adams LC; Jurmeister P; Ralla B; Bressem KK; Fahlenkamp UL; Engel G; Siepmann S; Wagner M; Hamm B; Busch J; Makowski MR
Eur Radiol; 2019 Nov; 29(11):5832-5843. PubMed ID: 30887194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
